Jackson Streeter
Partner @ DeepWork Capital
Lexington, United States
Jackson Streeter is a Series A investor at DeepWork Capital in Lexington focused on Therapeutics and Biotechnology. Dr. Streeter was appointed Chief Executive Officer of the Institute for the Commercialization of Public Research in March 2016. Prior to joining the Institute, Dr. Streeter served as the CEO of Banyan Biomarkers of Alachua, FL. During his time the company received over $75M in contracts and grants with the Department of Defense and raised $10M inprivate investment for the development of a first ever blood test for traumatic brain injury.Prior to serving as CEO of Banyan Biomarkers, Dr. Streeter founded and served as CEO for PhotoThera, Inc. where he raised over $120M in private capital and was responsible for the design and management of five U.S. and international clinical trials. He was also the co-founder of American Veterinary Laser, inventor of over twenty patents and author on multiple scientific publications. Dr. Streeter has served on the following boards and executive committees: Florida Research Consortium, Governor’s Life Science Task Force for the State of Florida, FBI counter terrorism south east working group, Walter H. Coulter Center Committee at the University of Miami and the Gainesville Chamber of Commerce Board of Directors.Dr. Streeter served as an Officer in the U.S. Navy, completing a general surgery internship at Naval Regional Medical Center in Portsmouth, Virginia and then primary Flight School at Naval Air Station Pensacola, Florida. During his military service, he was the first Naval Flight Surgeon selected as a TOPGUN staff instructor, served on several overseas deployments and was awarded the Navy Achievement Medal and the Navy Commendation Medal. He earned his B.S. degree in Biology from the University of Nevada Reno and his M.D. from the University Of Nevada School Of Medicine.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jackson Streeter invests in
Stages Jackson Streeter invests in
Countries Jackson Streeter invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 2 (50%)
- Biotechnology 2 (50%)
- Medical 1 (25%)
- Health Care 1 (25%)
- Medical Device 1 (25%)
Stage
- Series A 2 (50%)
- Series B 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significantimprovement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program.Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA. | $9M / Series B / Jan 16, 2024 | ||
| Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases | $5M / Series A / Aug 01, 2022 | ||
| Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M / Series A / May 03, 2021 | ||
| Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $5M / Series A / Nov 30, 2020 |
Co-Investors
About DeepWork Capital
DeepWork Capital, a Florida-based venture capital firm, invests in high-growth early-stage companies in the technology and life science sectors through proprietary and public committed capital funds. The Firm partners with visionary entrepreneurs building world-changing companies and supports portfolio companies' successes with activeengagement. For additional information, please see https://www.deepworkcapital.com.
DeepWork Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Benjamin Patz
Co-founder and Managing Partner
|
|||
|
Jackson Streeter
Partner
|
|||
Kathy Chiu
Co-founder and General Managing Partner
|
|||
Mitchel Laskey
Co-Founder and Managing General Partner
|
|||
Kenneth Hall
Vice President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jackson Streeter invest in?
Jackson Streeter invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jackson Streeter?
Public channels for Jackson Streeter include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jackson Streeter last invest?
The most recent investment recorded for Jackson Streeter closed in Jan 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
